Company Profiles

driven by the PitchBook Platform

Acumen Pharmaceuticals

Acumen Pharmaceuticals
1996 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$24.3M TOTAL AMOUNT RAISED
8 INVESTORS
Description

Developer of therapeutics and diagnostics designed to treat Alzheimer's disease and other memory-related disorders. The company's therapeutics and diagnostics develop ACU-193, the lead antibody within the Acumen ADDL-Select program which is fully humanized, IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers and potently blocks their deleterious actions, enabling patients to recover faster from degenerative disorders which result from the aging of brain.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
4435 North First Street
Suite 360
Livermore, CA 94551
United States

+1 (925) 368-8508
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Acumen Pharmaceuticals’s full profile, request a free trial.

Acumen Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 28-Sep-2015 $24.3M Completed Generating Revenue
4. Later Stage VC (Series A) 14-May-2013 0000 000.00 000.00 Completed Generating Revenue
3. Convertible Debt 25-Jun-2008 00000 00.000 Completed Generating Revenue
2. Convertible Debt 07-Aug-2006 $1.75M $3.45M Completed Generating Revenue
1. Later Stage VC 31-Mar-2004 $1.7M $1.7M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding request access »

Acumen Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
dummy 00,000,000 00.0 00.0 00 00.0 00.000
Series A3 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A2 13,273,453 $0.000100 8% $0.5 $0.5 1x $0.5 18.96%
Series A1 1,397,206 $0.000100 8% $0.5 $0.5 1x $0.5 2%
To view this company’s complete Cap Table request access »

Acumen Pharmaceuticals Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BVF Partners PE/Buyout Minority 000 0000 000000 0
GDBA Investments Venture Capital Minority 000 0000 000000 0
Glynn Capital Management Venture Capital Minority 000 0000 000000 0
Individual Investor Angel (individual) Minority 000 0000 000000 0
NeuroVentures Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Acumen Pharmaceuticals Executive Team (2)

Name Title Board
Seat
Contact
Info
William Goure Ph.D Chief Operating Officer
Daniel O'Connell Chief Executive Officer, Board Member & President

Acumen Pharmaceuticals Board Members (6)

Name Representing Role Since Contact
Info
Franz Hefti Ph.D Acumen Pharmaceuticals Board Member 000 0000
Grant Krafft Ph.D Self Co-Founder, Chief Scientific Adviser and Chairman of the Board of Directors 000 0000
Jeffrey Ives Ph.D Self Board Member 000 0000
Mark Lampert BVF Partners Board Member 000 0000

2 Former Board Members

You’re viewing 4 of 6 board members. Get the full list »